DelveInsight has launched a new report on “Ulcerative Colitis – Market Insights, Epidemiology, and Market Forecast-2032”.
Some of the key facts of the Ulcerative Colitis Market Report:
- As per DelveInsight’s analysis, the total diagnosed cases of UC in the 7MM were 1,577,979 in 2020.
- In the 7MM, the age-specific diagnosed cases of UC were 946,787, 441,834, 173,578, and 15,780 for the age group less than 18–44 years, 45–64 years, 65–84 years, and ≥85 years, in 2020.
- According to DelveInsight’s analysis, in the 7MM, 710,091 mild and 867,888 moderate-to-severe cases of UC were observed in 2020.
- In the 7MM, the total treated cases of UC were observed as 781,100 cases in 2020, which is expected to rise in the coming years.
Key benefits of the report:
- Ulcerative Colitis market report covers a descriptive overview and comprehensive insight of the Ulcerative Colitis Epidemiology and Ulcerative Colitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
- The Ulcerative Colitis market report provides insights on the current and emerging therapies.
- Ulcerative Colitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
- The Ulcerative Colitis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Ulcerative Colitis market.
Got queries? Click here to know more about Ulcerative Colitis Market Landscape.
Ulcerative Colitis Overview
Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of the digestive tract. The exact cause of IBD is unknown, but it is the result of a defective immune system.
Two major types of IBD are Ulcerative Colitis (UC) and Crohn’s Disease (CD). UC is limited to the colon or large intestine. CD, on the other hand, can involve any part of the gastrointestinal tract from the mouth to the anus. Approximately 10% of cases of IBD exhibit the features of both CD and UC. These are typically known as Indeterminate Colitis (IC).
There are different types of UC, categorized by the cause of the disease: Ulcerative proctitis, Proctosigmoiditis, Left-sided colitis (also limited or distal colitis), Pancolitis, and Extensive Colitis.
The dynamics of the Ulcerative Colitis market is anticipated to change in the coming years owing to the expected launch of emerging therapies by companies such as AbbVie and Boehringer Ingelheim, Eli Lilly and Company, Janssen, Galapagos/Gilead, Theravance Biopharma, and Janssen, Arena, Landos Biopharma, and others during the study period 2019-2032.
Ulcerative Colitis Pipeline Therapies and Key Companies
- Risankizumab (ABBV-066): AbbVie and Boehringer Ingelheim
- Mirikizumab (LY3074828): Eli Lilly and Company
- Tremfya (Guselkumab): Janssen
- Filgotinib: Galapagos/Gilead
- Izencitinib (TD-1473): Theravance Biopharma and Janssen
- Etrasimod (APD334): Arena
- BT-11: Landos Biopharma
Ulcerative Colitis Market Drivers
- Involvement of Digital technology
- Rich emerging pipeline
- Increasing Prevalence of Ulcerative Colitis
Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Ulcerative Colitis Patient Share (%) Overview at a Glance
5. Ulcerative Colitis Market Overview at a Glance
6. Ulcerative Colitis Disease Background and Overview
7. Ulcerative Colitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Ulcerative Colitis
9. Ulcerative Colitis Current Treatment and Medical Practices
10. Unmet Needs
11. Ulcerative Colitis Emerging Therapies
12. Ulcerative Colitis Market Outlook
13. Country-Wise Ulcerative Colitis Market Analysis (2019-2032)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Ulcerative Colitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Ulcerative Colitis Pipeline
“Ulcerative Colitis Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Ulcerative Colitis market. A detailed picture of the Ulcerative Colitis pipeline landscape is provided, which includes the disease overview and Ulcerative Colitis treatment guidelines.
Ulcerative Colitis Epidemiology
DelveInsight’s ‘Ulcerative Colitis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Ulcerative Colitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/